The estimated Net Worth of Glenn Goddard is at least $1.63 Million dollars as of 3 January 2024. Mr Goddard owns over 5,365 units of Intellia Therapeutics Inc stock worth over $821,440 and over the last 11 years he sold NTLA stock worth over $248,362. In addition, he makes $562,448 as Exec. VP and CFO & Treasurer at Intellia Therapeutics Inc.
Mr has made over 27 trades of the Intellia Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 5,365 units of NTLA stock worth $158,053 on 3 January 2024.
The largest trade he's ever made was exercising 30,000 units of Intellia Therapeutics Inc stock on 30 August 2021 worth over $569,700. On average, Mr trades about 5,446 units every 96 days since 2013. As of 3 January 2024 he still owns at least 40,585 units of Intellia Therapeutics Inc stock.
You can see the complete history of Mr Goddard stock trades at the bottom of the page.
Glenn G. Goddard is the Exec. VP, CFO & Treasurer at Intellia Therapeutics Inc.
As the Exec. VP and CFO & Treasurer of Intellia Therapeutics Inc, the total compensation of Mr Goddard at Intellia Therapeutics Inc is $562,448. There are 7 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of $1,762,490.
Mr Goddard is 50, he's been the Exec. VP and CFO & Treasurer of Intellia Therapeutics Inc since . There are 14 older and 4 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
Glenn's mailing address filed with the SEC is C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE, MA, 02139.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over $210,567,884 worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth $23,117,886 . The most active insiders traders include Carl L Gordon, Jean Francois Formela, and Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $1,357,638. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth $9,287.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: